Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.
The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.
DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.
This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.
Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.
A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.
Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.
Editorial Board member Jay Shubrook succinctly delivers his strategies for initiating insulin therapy for the first time in patients with type 2 diabetes [read more].
In this paper, the authors report on the current scientific evidence on the effectiveness of continuous glucose monitoring sensor technology in the prevention of severe hypoglycemia and hypoglycemia unawareness [read more]. Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6
The addition of linagliptin to stable insulin treatment improves glycemic control without increasing the risk for clinically important hypoglycemia among older individuals with type 2 diabetes, randomized trial findings suggest.
Patients initiating a flexible combination of basal insulin plus a glucagon-like peptide-1 receptor agonist have similar improvements in glycemic control to those initiating a fixed combination, but with greater weight loss, real-world study data show.
Almost one in 10 people with type 2 diabetes who begin basal insulin therapy through the Medicare health program experience hypoglycemia within 6 months, US research suggests.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
